Eli Lilly Strikes $1 Billion Deal with Innovent for Checkpoint Inhibitor

Eli Lilly will aim a checkpoint inhibitor it co-developed for the Chinese market at the United States and other western markets.

This morning, Eli Lilly and China-based Innovent Biologics expanded a strategic alliance involving TYVYT (sintilimab injection), an anti-PD-1 monoclonal antibody immuno-oncology medicine developed by the two companies for use in China. Lilly will pay Innovent $200 million in upfront monies to license the checkpoint inhibitor for the U.S. as well as other markets.